# Top
#### kind: BigAI
#### area: Bio
#### stance: 
## Sections
### LAMP
#### pri: 
#### contacts: 
#### cool: 
#### job: 
### Cash
#### cash_trend: spiking
#### cash: 
#### cash_available: 214
#### funding: 0.10
### Coolness
#### cool_why: 
#### cool_mission: 
#### cool_balance: 
#### cool_dan: 
#### mission: 
To tackle the most challenging design problems in drug discovery and address unmet patient needs ￼.
### Deep Learning Projects (DLP)
#### dlp: 
#### dlproj1: Generative Peptide Design Platform [*no direct link available*]
#### dlproj2: AI-Driven Macrocycle Discovery [*no direct link available*]
### Job Postings
#### job_why: 
#### job_bay: —
#### job_remote: Sr. Director of Technology and Product Development (Remote)
### Toxicity
## Misc Fields
#### bam:
#### dlp_:
### funding_justification: Limited data; guessed ~$5M in 2021 (~48 months ago); base=5/49≈0.10
### proj1: Iambic Pipeline (AI-designed oncology drug candidates)
### justification: 
Iambic (formerly Entos) is a biotech startup using generative AI for drug discovery. It has developed physics-informed generative models to design new molecular therapeutics and is advancing multiple AI-designed cancer drugs through trials, showcasing how generative diffusion models can propose novel drug candidates [oai_citation_attribution:83‡eweek.com](https://www.eweek.com/artificial-intelligence/generative-ai-startups/#:~:text=Iambic%20Therapeutics) [oai_citation_attribution:84‡eweek.com](https://www.eweek.com/artificial-intelligence/generative-ai-startups/#:~:text=,therapeutics%2C%20NeuralPlexer%2C%20OrbNet%2C%20PropANE%2C%20Magnet)
### proj2: OrbNet & Generative Chemistry (AI platforms for molecule design)
### recent_funding: Closed $50M Series B extension in Jun 2024 ￼ (Series B total $150M by 2024)
### sdfsdfsfsfds: foo
